4//SEC Filing
Hudson Thomas J 4
Accession 0001179110-22-001509
CIK 0001551152other
Filed
Feb 21, 7:00 PM ET
Accepted
Feb 22, 5:33 PM ET
Size
13.4 KB
Accession
0001179110-22-001509
Insider Transaction Report
Form 4
AbbVie Inc.ABBV
Hudson Thomas J
SVP, R&D and CSO
Transactions
- Award
Common Stock, $0.01 par value
2022-02-17+2,530→ 43,544 total - Award
Common Stock, $0.01 par value
2022-02-17+11,642→ 41,014 total - Award
Common Stock, $0.01 par value
2022-02-17+9,483→ 53,027 total - Award
Common Stock, $0.01 par value
2022-02-17+6,609→ 59,636 total - Award
Option (Right to Buy)
2022-02-17+25,394→ 25,394 totalExercise: $144.54From: 2023-02-17Exp: 2032-02-16→ Common Stock (25,394 underlying)
Footnotes (5)
- [F1]Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022.
- [F2]Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022.
- [F3]Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022.
- [F4]Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022.
- [F5]Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 8,465 on February 17, 2023, 8,465 on February 17, 2024, and 8,465 on February 17, 2025.
Documents
Issuer
AbbVie Inc.
CIK 0001551152
Entity typeother
Related Parties
1- filerCIK 0001781947
Filing Metadata
- Form type
- 4
- Filed
- Feb 21, 7:00 PM ET
- Accepted
- Feb 22, 5:33 PM ET
- Size
- 13.4 KB